Mayo Researchers Find Cancer Biopsies Do Not
Promote Cancer Spread
JACKSONVILLE,
Fla. — A study of more than 2,000 patients by researchers at Mayo Clinic’s
campus, has dispelled the myth that cancer biopsies cause cancer to spread. In
the Jan. 9 online issue of Gut, they show that patients who received a biopsy
had a better outcome and longer survival than patients who did not have a
biopsy.
The researchers
studied pancreatic cancer, but the findings likely apply to other cancers
because diagnostic technique used in this study — fine needle aspiration — is
commonly used across tumor types, says the study’s senior investigator and
gastroenterologist Michael Wallace, M.D.
Fine needle
aspiration is a minimally invasive technique that uses a thin and hollow needle
to extract a few cells from a tumor mass. A long-held belief by a number of
patients and even some physicians has been that a biopsy can cause some cancer
cells to spread.
While there
have been a few case reports that suggest this can happen — but very rarely —
there is no need for patients to be concerned about biopsies, says Dr. Wallace.
“This study
shows that physicians and patients should feel reassured that a biopsy is very
safe,” he says. “We do millions of biopsies of cancer a year in the U.S., but
one or two case studies have led to this common myth that biopsies spread
cancer.”
Biopsies offer
“very valuable information that allow us to tailor treatment. In some cases, we
can offer chemotherapy and radiation before surgery for a better outcome, and
in other cases, we can avoid surgery and other therapy altogether,” Dr. Wallace
says.
Surgery for
pancreatic cancer is “a very big operation,” and “most people should want to
make sure they have cancer before they undergo surgery,” he says. One study has
shown that 9 percent of patients who underwent surgery because of suspected
pancreatic cancer actually had benign disease.
Dr. Wallace and
his team have conducted two separate studies to examine the risk of biopsy.
In a 2013 study
published in Endoscopy,
the researchers examined outcomes in 256 pancreatic cancer patients treated at
Mayo Clinic in Jacksonville, Florida. They found no difference in cancer
recurrence between 208 patients who had ultrasound-guided fine needle
aspiration (EUS-FNA) and the 48 patients who did not have a biopsy.
In the current
study, they examined 11 years (1998–2009) of Medicare data on patients with
non-metastatic pancreatic cancer who underwent surgery. The researchers
examined overall survival and pancreatic cancer-specific survival in 498
patients who had EUS-FNA and 1,536 patients who did not have a biopsy.
During a mean
follow-up time of 21 months, 285 patients (57 percent) in the EUS-FNA group and
1,167 patients (76 percent) in the non-EUS-FNA group died. Pancreatic cancer
was identified as the cause of death for 251 patients (50 percent) in the
EUS-FNA group and 980 patients (64 percent) in the non-EUS-FNA group.
Median overall
survival in the EUS-FNA group was 22 months compared to 15 months in the
non-EUS-FNA group.
“Biopsies are
incredibly valuable. They allow us to practice individualized medicine —
treatment that is tailored for each person and designed to offer the best
outcome possible,” Dr. Wallace says.
Source: Mayo Clinic News Network